List view / Grid view
A significant hurdle in optimising antibody therapeutics is the screening of successive rounds of large libraries of mutant variants in order to recognise the ideal candidate.
The number of oligonucleotide-based platforms on the market is constantly increasing and has led to the emergence of innovative nucleic acid-based therapeutic modalities such as CRISPR-Cas, sgRNAs or mRNAs.
Monoclonal antibodies are used in a wide range of applications, such as basic research, biopharmaceutical development and in vitro diagnostics.
This In-Depth Focus features articles highlighting the importance of effective data management strategies as well as the recent trends in upstream bioprocessing.
The articles in this antibodies In-Depth Focus assess the methods used to develop antibody therapeutics and the evolution of this area of medicine to identify drug targets.
In this In-Depth Focus are articles on how genomics could revolutionise clinical treatment and an insight into the promise and pitfalls of using CRISPR.
This issue includes an investigation into utilising recombinant antibodies for research, a highlight on protein design using computational methods and an examination of the advances in genomic medicine. Also in the issue are articles on next generation sequencing and upstream bioprocessing.
This article highlights five of the latest findings that could be used in the development or design of new therapies to treat Parkinson’s disease.
A report from scientists at the Moscow Institute of Physics and Technology highlights the advantages and disadvantages of serial femtosecond X-ray crystallography. This article investigates the review, focusing on its role in drug development.
Dr Shona Lang investigates the advantages and disadvantages of using organoids within R&D, highlighting the most important questions to ask before using these models.
AI has applications in many areas of research, including genomics. Slavé Petrovski of AstraZeneca reveals how AI is used in the study of the human genome and how it may evolve in the future.
Claus Bendtsen at AstraZeneca reveals how AI can be used to improve our understanding of disease, to help identify the causes of conditions and aid in drug discovery.
Designing new drug molecules is crucial to R&D. Dr Sam Genway suggests that one way to improve and speed up this process is using AI inspired by language translation.
Imaging methods are used by scientists to identify therapeutic targets and improve drug efficacy. This article lists five of the latest developments for imaging techniques.
A review has been published by experts in neurodegeneration research, detailing six ways to improve dementia research. This article investigates one of these suggestions, focusing on how we can improve drug target identification.
